HAINAN HAIYAO(SZ:000566) Xin Lang Cai Jing·2026-01-09 12:22Core Viewpoint - The announcement highlights the successful completion of Phase IIa clinical trials for the innovative drug Paiengabin, developed by Haikou Pharmaceutical Factory in collaboration with the Shanghai Institute of Materia Medica, indicating positive preliminary results for both primary and secondary clinical endpoints [1] Group 1 - The drug Paiengabin is classified as a Class 1 chemical drug and is a new type of antiepileptic medication [1] - Paiengabin acts as a KCNQ potassium channel agonist and is currently the only drug of its kind in development globally, with no existing market products [1] - The medication is intended for the treatment of refractory epilepsy, addressing a significant unmet medical need in the epilepsy treatment landscape [1]